Home Antibody All anti-MYBL2 antibodies
Anti-MYBL2 PHOSPHO Antibody EPR2204Y
Also for MYBL2 (NM_002466)
|A phospho specific peptide corresponding to residues surrounding threonine 487 of human B-Myb was used as an immunogen. This antibody detects B-Myb phosphorlyated on threonine 487.|
|Mouse, Rat, Human
||Lot dependent; please refer to CoA along with shipment
|WB, IHC, IF, FC
||ChIP: Use at an assay dependent concentration; ICC/IF: 1:100 - 1:250; FC: 1:50; WB: 1:500 - 1:1000; IP: 1:40; IHC-P: 1:100 - 1:250
|PBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%|
|Tissue culture supernatant
|Homo sapiens v-myb avian myeloblastosis viral oncogene homolog-like 2 (MYBL2), transcript variant 1|
Entrez Gene 4605 Human
Entrez Gene 17865 Mouse
Entrez Gene 296344 Rat
|Expression of the B-Myb transcription factor is upregulated during late G1 phase of the cell cycle by an E2F-dependent transcriptional mechanism. B-Myb is specifically phosphorylated during S phase, suggesting that a cyclin-dependent kinase (Cdk) regulates its activity. Consistent with this notion, the S phase-specific cyclin A/Cdk2 was found previously to enhance B-Myb transactivation activity in cotransfected cells. There is evidence that B-Myb is a direct physiological target for cyclin A/Cdk2. Data indicate that phosphorylation by cyclin A/Cdk2 is directly involved in enhancing B-Myb transactivation activity and that levels of endogenous cyclin A/Cdk2 activity may contribute to cell line-specific B-Myb function (1). Nuclear entry of B-Myb is dependent on multiple nuclear localization signals (NLS's). Mutagenesis of the putative NLS's of B-Myb has identified two separate NLS's, NLS1 and NLS2. Each of the two NLS's is essential for efficient nuclear targeting (2). |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot - B MyB (phospho T487) antibody [EPR2204Y]; All lanes : Anti-B MyB (phospho T487) antibody [EPR2204Y] - ChIP Grade at 1/1000 dilution.Lane 1 : Raji cell lysate, untreated.Lane 2 : Raji cell lysate treated with TPA + IGF.Lysates/proteins at 10 ug per lane.Secondary.Goat anti-rabbit HRP at 1/1000 dilution.Predicted band size : 79 kDa.Observed band size : 110 kDa .
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - B MyB (phospho T487) antibody [EPR2204Y]; TA301225, at 1/100 dilution, staining B MyB in human urinary bladder carcinoma by immunohistochemistry using paraffin-embedded tissue.
Immunocytochemistry/ Immunofluorescence - B MyB (phospho T487) antibody [EPR2204Y]; TA301225, at 1/100 dilution, staining B MyB in HeLa cells by immunofluorescence.
Flow Cytometry-Anti-B MyB (phospho T487) antibody [EPR2204Y](TA301225); Overlay histogram showing HeLa cells stained with TA301225 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody for 30 min at 22°C. The secondary antibody used was DyLight 488 goat anti-rabbit IgG (H+L) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monclonal) (1ug/1x10^6 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.